公开(公告)号：US20180186855A1

公开(公告)日：2018-07-05

申请号：US15466541

申请日：2017-03-22

Applicant: ALECTOR LLC

Inventor： Arnon ROSENTHAL

IPC: C07K14/725 ,  A61K35/14 ,  A61K49/00 ,  C07K14/715 ,  C07K16/18 ,  C07K14/705 ,  A61K39/00

CPC classification number: C07K14/7051 ,  A01K2227/105 ,  A01K2267/0312 ,  A61K35/15 ,  A61K38/00 ,  A61K39/0007 ,  A61K48/00 ,  A61K48/005 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61P25/28 ,  C07K14/4711 ,  C07K14/70517 ,  C07K14/7153 ,  C07K16/18 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C12N5/00 ,  C12N2740/16043

Abstract: The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent a neurological disease, disorder, or injury.

公开(公告)号：US20230312712A1

公开(公告)日：2023-10-05

申请号：US18174499

申请日：2023-02-24

Applicant: Alector LLC

Inventor： Tina SCHWABE ,  Eric BROWN ,  Philip KONG ,  Ilaria TASSI ,  Seung-Joo LEE ,  Arnon ROSENTHAL ,  Robert PEJCHAL ,  Nels P. NIELSON

IPC: C07K16/28 ,  A61P25/28

CPC classification number: C07K16/2803 ,  A61P25/28 ,  C07K2317/71 ,  C07K2317/90 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2039/505

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230303681A1

公开(公告)日：2023-09-28

申请号：US17820686

申请日：2022-08-18

Applicant: ALECTOR LLC

Inventor： Arnon ROSENTHAL ,  Eric BROWN ,  Tina SCHWABE ,  Angie YEE ,  Herve RHINN

IPC: C07K16/28

CPC classification number: C07K16/28 ,  C07K2317/34 ,  C07K2317/56

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230142579A1

公开(公告)日：2023-05-11

申请号：US17821010

申请日：2022-08-19

Applicant: Alector LLC

Inventor： Philip KONG ,  Herve RHINN ,  Tina SCHWABE ,  Angie YEE ,  Ilaria TASSI ,  Muhammad Abbas ALHAWAGRI ,  Arnon ROSENTHAL

IPC: C07K16/28

CPC classification number: C07K16/28 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/71

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230024528A1

公开(公告)日：2023-01-26

申请号：US17782127

申请日：2020-12-04

Applicant: Alector LLC

Inventor： Tina SCHWABE ,  Ilaria TASSI ,  Arnon ROSENTHAL ,  Hua LONG ,  Santiago Viveros SALAZAR

IPC: C07K16/28 ,  A61P25/28

Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.

公开(公告)号：US20220411503A1

公开(公告)日：2022-12-29

申请号：US17831336

申请日：2022-06-02

Applicant: Alector LLC

Inventor： Kate MONROE ,  Helen LAM ,  Arnon ROSENTHAL ,  Seung-Joo LEE ,  Francesca AVOGADRI-CONNORS ,  William MONTEITH

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20220281976A1

公开(公告)日：2022-09-08

申请号：US17752606

申请日：2022-05-24

Applicant: Alector LLC

Inventor： Arnon ROSENTHAL ,  Kate MONROE ,  Francesca AVOGADRI-CONNORS

IPC: C07K16/28 ,  A61K47/68 ,  C12N15/85 ,  A61P35/00 ,  C12N15/62

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20210317208A1

公开(公告)日：2021-10-14

申请号：US17272083

申请日：2019-08-30

Applicant: Alector LLC

Inventor： Patricia CULP ,  Helen LAM ,  Wei-Hsien HO ,  Leonard G. PRESTA ,  Arnon ROSENTHAL

IPC: C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20210246204A1

公开(公告)日：2021-08-12

申请号：US16972840

申请日：2019-06-07

Applicant: Alector LLC

Inventor： Patricia CULP ,  Seung-Joo LEE ,  Helen LAM ,  Wei-Hsien HO ,  Arnon ROSENTHAL

IPC: C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20210122817A1

公开(公告)日：2021-04-29

申请号：US16965675

申请日：2019-01-31

Applicant: Alector LLC

Inventor： Philip KONG ,  Herve RHINN ,  Tina SCHWABE ,  Angie YEE ,  Arnon ROSENTHAL

IPC: C07K16/28 ,  A61P25/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A6A polypeptide, e.g., a mammalian MS4A6A or human MS4A6A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.